ACE-LY-004 phase II trial results substantiate established efficacy and safety profile of Calquence in mantle cell lymphoma.- AstraZeneca.
Related news and insights
Incyte has announced updates regarding the clinical development of parsaclisib, the Company’s next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3K?), and MCLA-145, its CD137/PD-L1 bispecific antibody co-developed under a global collaboration and license agreement with Merus.
Kite, a Gilead Company announced that the European Commission has granted conditional marketing authorization for Tecartus (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19).
Bristol Myers Squibb announced data from multiple studies evaluating lisocabtagene maraleucel (liso-cel), an investigational CD19-directed chimeric antigen receptor (CAR) T cell therapy, in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in relapsed or refractory mantle cell lymphoma (MCL) were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.